HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Prazepam
w4020 · K-373 · W 4020 · Settima · Centrax · Prazene · Verstran · Trepidan
Identifikatoren & physikalische Daten
| CAS No. | 2955-38-6 |
|---|---|
| Summenformel | C19H17ClN2O |
| Durchschnittliche Molmasse | 324,8 g/mol |
| Monoisotopische Masse | 324,1029409 g/mol |
| SMILES | O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1 |
| InChIKey | MWQCHHACWWAQLJ-UHFFFAOYSA-N |
| PubChem CID | 4890 |
| ChEMBL | CHEMBL969 |
| ChEBI | CHEBI:8362 |
| EC No. | 220-975-8 |
| DTXSID | DTXSID4021181 |
| Lokaler Name | Prazepam |
Chemische & physikalische Eigenschaften
| XLogP | 3,6 |
|---|---|
| Polarare Oberfläche (TPSA) | 32,7 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 2 |
| Frei drehbare Bindungen | 3 |
| Schwere Atome | 23 |
| Formalladung | 0 |
| Komplexität | 482 |
| LogP (Verteilungskoeffizient) | 3.73 |
| Löslichkeit | 3.99e-03 g/LDissolve 0.25 g in alcohol R and dilute to 10 mL with the same solvent. The solution is clear (2.2.1) and colourless (2.2.2, Method II).9.095mg/L(25 ºC) |
| Schmelzpunkt | 145-146 °C145 - 146 °C145-146° |
| Physical Description | Solid |
| Kovats Retention Index | 2648265126242630265226762679269426382610265526412650.12620261926562746.92646.32633.22660.52685 |
| Collision Cross Section | 174 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| Siedepunkt | 538.5±50.0 °C(Predicted) |
| Dichte | 1.1660 (rough estimate) |
| Brechungsindex | 1.5790 (estimate) |
| Flammpunkt | 11 °C |
| Lagerbedingungen | 2-8°C |
| Aggregatzustand | Solid |
| pKa (Säurekonstante) | pKa 2.94 (Uncertain) |
| Farbe | White to Off-White |
| Hauptanwendungen | pharmaceutical (small molecule) |
| InChI | 1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2 |
| InChIKey | MWQCHHACWWAQLJ-UHFFFAOYSA-N |
| SMILES | Clc1ccc2N(CC3CC3)C(=O)CN=C(c4ccccc4)c2c1 |
| EPA chemische Informationen | 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl- (2955-38-6) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 33.3% (1 of 3) of reports.WarningH336 (66.7%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposureNarcotic effects]H361 (66.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]H362 (33.3%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]P203, P260, P261, P263, P264, P270, P271, P280, P304+P340, P318, P319, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 1 of 3 reports by companies.There are 2 notifications provided by 2 of 3 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Regulatorische Informationen | DEA schedule IV controlled substance2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right. |
| Weitere Sicherheitsinformationen | IMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-: Human health tier I assessmentIMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-: Environment tier I assessment |
| Hazard Classes and Categories | STOT SE 3 (66.7%)Repr. 2 (66.7%)Lact. (33.3%) |
| Treatment | General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended. |
| Gesundheitliche Auswirkungen | They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. |
| Expositionspfade | Oral |
| Toxizitätsübersicht | Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation. |
| Signs and Symptoms | Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored. |
| Carcinogen Classification | PrazepamGroup 3: Not classifiable as to its carcinogenicity to humansVolume 66: (1996) Some Pharmaceutical Drugs3, not classifiable as to its carcinogenicity to humans. (L135) |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)PrazepamDILI PositiveDOI:10.1016/j.drudis.2019.09.022 |
| Wassergefährdungsklasse (WGK) | 2 |
| UN-Transportnummer | 3249 |
| Zollcode | 2933910000 |
| RTECS-Nr. | DF2368000 |
| R-Sätze (R) | 11-23/24/25-39/23/24/25 |
| Gefahrensymbole | F,T |
| Sicherheitshinweise (S) | 22-24/25-45-36/37-16-7 |
| Gefahrenklasse | 6.1(b)STOT SE 3 |
| Verpackungsgruppe | III |
| Lagerklasse | 11 - Combustible Solids |
Anwendungen & Verwendung
Beschreibung
Prazepam (Item No. 18358) is an analytical reference material categorized as a benzodiazepine. Prazepam is regulated as a Schedule IV compound in the United States. This product is intended for research and forensic applications.
Verwenden
Sedative-hypnotic.